An influential New Mexico lawmaker is once again pushing to protect state 340B providers from drugmaker contract pharmacy restrictions after [...] …
Category: PBMs and Payers
Federal lawmakers late last week approved a pared-down, must-pass federal spending bill, which cut back on health center funding and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
U.S. House Republican leaders this week unveiled and then quickly backed off of a year-end federal spending package following internal [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Delaware Gov. John Carney (D) late last week signed into law a bill to prohibit “discrimination against 340B entities by [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
More than two-thirds of 340B contract pharmacies are associated with pharmacy benefit managers (PBMs) through either vertical integration or contractual [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A key Republican lawmaker accused executives of the three largest pharmacy benefit managers (PBMs) of “abusing” the 340B program during [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Just days after a federal court in Mississippi denied Novartis’ attempt to block the state’s 340B contract pharmacy access law, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Massachusetts Senate on Thursday failed to adopt legislation that would have prohibited pharmacy benefit managers (PBMs) from imposing discriminatory [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Beacon Hill lawmakers are expected to vote Thursday on a proposal that would prohibit pharmacy benefit managers (PBMs) from imposing [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The rates 340B pediatric hospitals negotiate with payers for new pediatric oncology drugs often exceed a medication’s average sale price, [...] …